X

Drug Profile

Draflazine

Alternative Names: R 70380

Latest Information Update: 11 Jun 2000

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen L.P.
Developer Janssen L.P.; Nonindustrial source
Class Antiplatelets; Piperazines
Mechanism of Action Purinergic P1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Belgium (Unknown route)
11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Netherlands (Unknown route)
11 Jun 2000 Discontinued-Preclinical for Ischaemic heart disorders in Norway (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com